Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$981K Sell
7,636
-1,374
-15% -$161K 0.28% 81
2026
Q1
$1.08M Buy
9,010
+1,783
+25% +$206K 0.36% 65
2025
Q4
$767K Buy
7,227
+1,276
+21% +$120K 0.25% 83
2025
Q3
$504K Buy
5,951
+63
+1% +$5.19K 0.18% 121
2025
Q2
$471K Buy
5,888
+3,575
+155% +$284K 0.19% 112
2025
Q1
$209K Sell
2,313
-986
-30% -$92.1K 0.11% 167
2024
Q4
$331K Sell
3,299
-1,314
-28% -$135K 0.17% 119
2024
Q3
$527K Sell
4,613
-100
-2% -$11.9K 0.43% 57
2024
Q2
$587K Buy
4,713
+174
+4% +$22.4K 0.38% 55
2024
Q1
$602K Buy
4,539
+407
+10% +$50.2K 0.67% 36
2023
Q4
$454K Buy
+4,132
New +$429K 0.58% 52

Other funds holding MRK

Sunpointe's MRK Position: Q2 2026 in Review

Sunpointe reduced its Merck (MRK) stake by 15% in Q2 2026, selling an estimated $161K and leaving 7,636 shares worth $981K. The position accounts for 0.28% of the portfolio, ranked #81.

Sunpointe first reported a position in MRK in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.08M in Q1 2026. 3,833 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Sunpointe held 7,636 shares of Merck worth $981K as of Q2 2026.
  • Sunpointe sold 1,374 Merck shares in Q2 2026, an estimated $161K.
  • Merck made up 0.28% of Sunpointe's portfolio in Q2 2026, its #81 holding.
  • Sunpointe first reported a position in Merck in Q4 2023 and has held it in 11 quarters since.
  • Sunpointe's Merck position peaked at $1.08M in Q1 2026.
  • 3,833 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Sunpointe's 13F filing for Q2 2026, filed 24 Jul 2026.